After Ocaliva: US FDA Sees Breakthrough Potential In New Approaches To Liver Disease

New nods for Boehringer Ingelheim’s survodutide, Sagimet’s denifanstat and Mirum’s volixibat bring the FDA’s non-infectious liver disease breakthrough therapy designations to 15, with six designees already approved.